Growth in Furniture and Construction industry are said to be a major boost for the Formaldehyde market. Asia Pacific was the largest market for Formaldehyde accounting for 6.8 billion USD revenue in the year 2012. Some of the leading companies operating in the global market include Bayer MateriaScience, BASF SE, Dynea Oy, Hexion Specialty Chemicals, Celanese Corporation, Georgia Pacific Corporation, Formox and others. References Waterhouse, G. I. (2004).
The company was a result of a 1989 transatlantic merger, which set a world-wide trend of pharmaceutical company mergers. The Beecham Group was founded in 1842, when Thomas Beecham came out with his cure-all Beecham pills and powders. During the 1950s and 1960s, the company excelled in the research of antibiotics, discovering Amoxycillin, one of the most widely used anti-bacterial drugs John Smith opened his first drugstore in Philadelphia in 1830, the firm was renamed Smith, Kline & Company in 1875, after Malon Kline showed great entrepreneurial spirit. Drugs like Thorazine made SmithKline the leading pharmaceutical firm. Thorazine revolutionised the treatment of mental illness in the 1950s.
Alexion Pharmaceuticals was established in the United State in 1992 by the founder Leonard Bell and became a public company in 1996. Alexion Pharmaceutical is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. It is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company also involved in immune system research related to autoimmune diseases. The global headquarters and research operations are in New Haven, Conn. Alexion's approximately 3,000 employees around the world serve patients in 50 countries (Alexion.com).
PROJECT OVERVIEW AND MOTIVATION Since 2007 the global pharmaceutical scenario has witnessed an increasing number of big ticket deals such as Novartis’ and GlaxoSmithKline’s business swap (worth close to $23 million), Pfizer’s USD 100 billion offer for AstraZeneca, Bayer’s acquisition of Merck’s consumer care business for $14.2 billion (US Dollars) and Valeant’s $47 billion (US Dollars) offer for Allergan. With the growth in the developed markets slowing down, the next major focus is on the emerging markets. Amongst the emerging markets, the Indian scenario was considered to be very promising. Indian market provides various unique propositions which make it very attractive. These range
Scrophularia atropatana extract exerts cytotoxic and apoptotic activities on fibrosarcoma cell line Abstract Several studies established anti-tumor effects of herbal extracts and its ongoing application in cancer treatments. Scrophularia, a genus of the family Scrophulariaceae, has been known as a promising candidate for this purpose. In this study we sought to explore the cytotoxic effects and the cell death mechanism of Scrophularia atropatana extracts. We used MTT assay to measure the cytotoxic activity of the extracts of S. atropatana on the WEHI cell line and L929 as a non-malignant cell line. More assays were employed to determine and confirm its effect through apoptosis induction including: TUNEL assay, DNA fragmentation test, western
Its number of shares of common stock is outstanding and it is about 6,128,855,392. Their portfolio includes medicines and other well-known healthcare products. They manufacture products in five main areas which are; specialty care and oncology, animal health, primary care, nutrition and customer healthcare. They produce medicines and vaccines for diabetology, cardiology, neurology, immunology etc. Some of their drugs include diflucan (oral
PART(A) GlaxoSmithKline is a leading organization that has a long history in its field. It is important to shed the light on its history to have background information about its first operation and to refer to the factors that helped it to have its outstanding position in the field of business. GlaxoSmithKline began operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc, but their combined histories go back much further than that. During World War II, the company focused on producing pharmaceuticals for the war effort. Glaxo's parent company, Joseph Nathan & Company, was dissolved, and Glaxo became an independent public company in 1947.
Papaver somniferum(opium poppy) Introduction To Pharmaceutical Plants Pharmaceutical Plants are derived from genitically modified plants which are used as therapeutic compounds. It is used for the replacement of the traditional method of inoculating animals for Cell Culture Productions. These plants are also used to prevent diseases that have already been once deemed incurable. These plants are able to produce complex therapeutic proteins from plants cells. (Hortan 2012) These therapeutic proteins are seen in brands like Enevrel and Remicade for rheumatoid arthritis, Herceptin, a breast cancer treatment.
Among these the baby plant is Nagpur plant which will the biggest formulation unit for Lupin in coming year. Europe Lupin’s focus in the European Union encompasses Anti-Infectives, Cardiovascular, and CNS therapy areas, along with niche opportunities in segments like Oral Contraceptives, Dermatology and Ophthalmics. The company’s presence in France is by way of a trade partnership; in Germany, it operates through its acquired entity Hormosan Pharma GmbH (Hormosan); while the UK business is a direct-to-market initiative. Japan Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS). Lupin operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company Lupin acquired in 2007, and I’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011.
Problem Description Vinita Gupta, CEO of Lupin Ltd, the seventh largest pharmaceutical company is looking at both organic and inorganic growth opportunities, and eyeing some big-ticket acquisition including European market, where it has a very small presence as of now. On 23rd July 2015, the board of Lupin Pharmaceuticals gave an in-principle approval to raise up to Rs. 7500 crore. The company is reportedly looking at some big acquisitions and may utilize the funds for the purpose. The company has to come up with a financial plan that improves the value of the firm in short, medium and long-term.